

## Special Issue

# Recent Advances in Molecular Neuroimaging

### Message from the Guest Editor

The field of molecular neuroimaging has experienced significant advancements, with innovative imaging techniques playing a crucial role in understanding the nervous system and beyond. This Special Issue aims to showcase the latest developments in molecular imaging methods and technologies, as well as their clinical applications. We welcome submissions that explore the use of various imaging modalities, such as PET, SPECT, MRI, fMRI, and optical imaging, in the diagnosis, monitoring, and treatment of a wide range of diseases. Contributions that highlight the integration of artificial intelligence and machine learning to enhance image analysis and provide clinical decision support are particularly encouraged. Additionally, we are interested in studies that address the challenges and future directions in molecular neuroimaging, including the development of novel imaging probes and the translation of research findings into clinical practice. By covering a broad spectrum of applications, this Special Issue seeks to provide a comprehensive overview of the current state of molecular neuroimaging and its potential to transform medical diagnosis and treatment.

### Guest Editor

Dr. Wenliang Fan

1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2. Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430022, China
3. Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China

### Deadline for manuscript submissions

31 March 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/231785](https://mdpi.com/si/231785)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).